查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1741186

溶瘤病毒治疗市场按产品类型、应用、开发阶段、通路和地区划分

Oncolytic Virus Therapy Market, By Product Type, By Application , By Development Stage, By Distribution Channel, By Region
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

溶瘤病毒治疗市场规模预计在 2025 年为 1,780 万美元，预计到 2032 年将达到 8,730 万美元，2025 年至 2032 年的复合年增长率为 25.5%。

报告范围 报告详细信息
基准年 2024 2025年的市场规模 1780万美元
效能数据 2020-2024 预测期 2025-2032
预测期间：2025年至2032年的复合年增长率 25.50% 2032年价值预测 8730万美元

溶瘤病毒疗法是一种很有前景的癌症治疗方法，它利用工程病毒选择性地靶向和摧毁癌细胞，同时保护健康细胞。病毒性癌症疗法的概念可以追溯到 20 世纪初。随着基因工程的进步，这一领域在 20 世纪 90 年代获得了发展势头，科学家可以修改病毒以增强肿瘤特异性和治疗效果。溶瘤病毒可以感染癌细胞，在其中复製，并诱导细胞裂解或刺激针对肿瘤的免疫反应。正在进行的研究和开发重点是优化病毒平台、开发联合治疗以及将溶瘤病毒疗法的应用扩展到各种癌症类型。学术界、製药公司和研究机构之间的合作研究有可能推动新型癌症溶瘤病毒疗法的开发并推进癌症治疗方法。

市场动态

由于病毒工程的进步、对癌症生物学的更好理解、临床试验的成功以及对创新癌症治疗的需求，全球溶瘤病毒治疗市场正经历强劲增长。此外，对新癌症适应症的探索、改善治疗效果的联合治疗、个人化医疗方法以及开发具有增强特性的下一代病毒预计将在不久的将来带来光明的市场机会。市场趋势包括病毒治疗平台、标靶递送系统和免疫调节策略的进步，解决了这一领域的製造和商业化挑战。此外，市场参与者正专注于合作研究开发新药，预计将推动全球溶瘤病毒治疗市场的成长。例如，2023 年 6 月 29 日，后期临床阶段生物製药公司 Genelux Corporation 和 TVAX Biomedical, Inc. 宣布，美国专利商标局已授予一项专利，要求保护一种将疫苗增强过继 T 细胞疗法与溶瘤病毒辅助性治疗相结合的方法。该专利已独家授权给V2ACT Therapeutics, LLC，该公司是Generax和TVAX为开发和测试V2ACT免疫疗法而成立的合资公司。专利到期，为V2ACT免疫疗法增加了实质的智慧财产权保护。

然而，有限的临床证据、给药和分销方面的挑战、治疗相关的高成本以及治疗的副作用等因素预计将阻碍市场的成长。克服这些挑战对于最大限度地提高溶瘤病毒疗法的疗效并使其更广泛地普及至关重要。

研究的主要特点

  • 本报告对全球溶瘤病毒治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和复合年增长率。
  • 它还揭示了不同领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
  • 该报告根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，对全球溶瘤病毒治疗市场的主要企业进行了概述。
  • 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
  • 本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过全球溶瘤病毒治疗市场分析中使用的各种策略矩阵来简化决策。

目录

第一章 调查目的与前提条件

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告描述
    • 市场定义和范围
  • 执行摘要
  • 一致的机会图（COM）

第三章市场动态、法规与趋势分析

  • 市场动态
  • 病毒工程的进展
  • 增进对癌症生物学的理解
  • 临床试验成功案例
  • 创新癌症治疗的需求
  • 治疗费用高昂
  • 治疗的副作用
  • 寻找新的癌症适应症
  • 结合治疗以改善疗效
  • 个人化医疗方法
  • 影响分析
  • 监管情景
  • 产品发布/核准
  • PEST分析
  • 波特分析
  • 併购场景

4. 溶瘤病毒治疗市场-冠状病毒（COVID-19）大流行的影响

  • COVID-19流行病学
  • 供需侧分析
  • 经济影响

5. 溶瘤病毒治疗市场（依产品类型），2020 年至 2032 年

  • 介绍
  • 单纯疱疹病毒
  • 腺病毒
  • 痘苗病毒
  • 呼肠孤病毒
  • 麻疹病毒
  • 其他（新城疫病毒、水痘口炎病毒）

6. 溶瘤病毒疗法市场（按应用划分），2020 年至 2032 年

  • 介绍
  • 黑色素瘤
  • 乳癌
  • 头颈癌
  • 膀胱癌
  • 摄护腺癌
  • 肺癌
  • 其他（结肠癌等）

7. 溶瘤病毒治疗市场（依发展阶段划分），2020 年至 2032 年

  • 介绍
  • 商业的
  • 管道阶段
  • 临床前
  • 第一阶段
  • 第二阶段
  • 第三阶段

8. 溶瘤病毒治疗市场（依通路划分），2020 年至 2032 年

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

9. 溶瘤病毒治疗市场（按地区划分），2020 年至 2032 年

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 东南亚国协
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲
  • 中东
    • 海湾合作委员会国家
    • 以色列
    • 其他中东地区
  • 非洲
    • 北非
    • 中部非洲
    • 南非

第十章 竞争格局

  • Amgen Inc.
  • Merck & Co., Inc.
  • Oncolytics BIoTech Inc.
  • Circio Holding ASA
  • Akamis Bio
  • Vyriad, Inc.
  • SillaJen BIoTherapeutics
  • Cold Genesys Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Replimune Group Inc.
  • Genelux Corporation
  • Synthetic Biologics, Inc
  • Lokon Pharma AB
  • Elicera Therapeutics

第 11 章 章节

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5916

Oncolytic Virus Therapy Market is estimated to be valued at USD 17.8 Mn in 2025 and is expected to reach USD 87.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 17.8 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 25.50% 2032 Value Projection: USD 87.3 Mn

Oncolytic virus therapy is a promising approach to cancer treatment that utilizes modified viruses to selectively target and destroy cancer cells while sparing healthy cells. The concept for viruses for cancer treatment dates back to the early 20th century, when researchers observed tumor regression in patients with viral infections. The field gained momentum in the 1990s with advancements in genetic engineering, enabling scientists to modify viruses to enhance the tumor-specificity and therapeutic efficacy. Oncolytic viruses can infect cancer cells, replicate within them, and induce cell lysis or stimulate immune responses against the tumor. Ongoing research focuses on optimizing viral platforms, developing combination therapies, and expanding the application of oncolytic virus therapy to various cancer types. Collaborations between academia, pharmaceutical companies, and research institutions drive the development of novel oncolytic virus therapies and hold promise for advancing cancer treatment approaches.

Market Dynamics:

The global oncolytic virus therapy market is witnessing strong growth on account of growing advancements in viral engineering, increasing understanding of cancer biology, successful clinical trial results, and the need for innovative cancer treatments. Moreover, exploring new cancer indications, combining therapies for improved outcomes, personalized medicine approaches, and the development of next-generation viruses with enhanced characteristics are expected to bring bright market opportunities in the near future. The market trends include advancements in virotherapy platforms, targeted delivery systems, immune modulation strategies, and addressing manufacturing and commercialization challenges in the field. Moreover, market players are focused on developing novel drugs by collaborating, which is expected to drive the growth of global oncolytic virus therapy market. For instance, on June 29, 2023, Genelux Corporation, a late clinical-stage biopharmaceutical company, and TVAX Biomedical, Inc., a late clinical-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy. The patent has been exclusively licensed to V2ACT Therapeutics, LLC, a joint venture between Genelux and TVAX that was established for the purpose of developing and testing V2ACT immunotherapy. The patent expiry, prior to any patent term extension, will be in 2036 and will add substantial intellectual property protection for V2ACT immunotherapy.

However, limited clinical evidence, delivery and distribution challenges, high costs associated with treatment, and side effects of treatment are expected to hamper market growth. Overcoming these challenges is essential to maximizing the efficiency and broader adoption of oncolytic virus therapies.

Key features of the study:

  • This report provides in-depth analysis of the global oncolytic virus therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global oncolytic virus therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Circio Holding ASA, Akamis Bio, Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Synthetic Biologics, Inc., Lokon Pharma AB, and Elicera Therapeutics.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global oncolytic virus therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncolytic virus therapy market

Detailed Segmentation:

  • Global Oncolytic Virus Therapy Market, By Product Type:
    • Herpes simplex virus
    • Adenovirus
    • Vaccinia virus
    • Reovirus
    • Measles virus
    • Others (Newcastle disease virus, Vesicular stomatitis virus)
  • Global Oncolytic Virus Therapy Market, By Application:
    • Melanoma
    • Breast cancer
    • Head and neck cancer
    • Bladder Cancer
    • Prostate Cancer
    • Lung Cancer
    • Others (Colorectal Cancer, and among Others)
  • Global Oncolytic Virus Therapy Market, By Development Stage:
    • Commercial
    • Pipeline Phase
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
  • Global Oncolytic Virus Therapy Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Oncolytic Virus Therapy Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles:
    • Amgen Inc.
    • Merck & Co., Inc.
    • Oncolytics Biotech Inc.
    • Circio Holding ASA
    • Akamis Bio
    • Vyriad, Inc.
    • SillaJen Biotherapeutics
    • Cold Genesys Inc.
    • Sorrento Therapeutics, Inc.
    • Takara Bio Inc.
    • Replimune Group Inc.
    • Genelux Corporation
    • Synthetic Biologics, Inc.
    • Lokon Pharma AB
    • Elicera Therapeutics

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Oncolytic Virus Therapy Market, By Product Type
    • Global Oncolytic Virus Therapy Market, By Application
    • Global Oncolytic Virus Therapy Market, By Development Stage
    • Global Oncolytic Virus Therapy Market, By Distribution Channel
    • Global Oncolytic Virus Therapy Market, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Advancements in Viral Engineering
  • Increasing Understanding of Cancer Biology
  • Successful Clinical Trial Results
  • Need for Innovative Cancer Treatments
    • Restraints
  • High cost associated with treatment
  • Side effects of treatment
    • Opportunities
  • Exploring new cancer indications
  • Combining therapies for improved outcomes
  • Personalized medicine approaches
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Oncolytic Virus Therapy Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Oncolytic Virus Therapy Market , By Product Type, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021-2032
    • Segment Trends
  • Herpes Simplex Virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Adenovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Vaccinia virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Reovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Measles virus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others (Newcastle disease virus, Vesicular stomatitis virus)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Oncolytic Virus Therapy Market, By Application, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Breast cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Head and neck cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Bladder Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Prostate Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,( US$ Mn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Others (Colorectal Cancer, and among Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Oncolytic Virus Therapy Market, By Development Stage, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Commercial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Pipeline Phase
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III

8. Oncolytic Virus Therapy Market , By Distribution Channel, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Oncolytic Virus Therapy Market, By Region, 2020-2032, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Country, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, For Country 2021-2032
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • U.S.
      • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • U.K
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Development Stage, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Oncolytics Biotech Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Circio Holding ASA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Akamis Bio
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Vyriad, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • SillaJen Biotherapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cold Genesys Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sorrento Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Takara Bio Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Replimune Group Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Genelux Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Synthetic Biologics, Inc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Lokon Pharma AB
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Elicera Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

11. Section

  • Research Methodology
  • About us